Yung Zip Chemical Ind Co Ltd (4102) Fair Value & Analysis

Healthcare · TW · Market cap 856M TWD

Below-average quality, and screening another 78% overvalued on our models.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case (5.68 TWD). The favourable scenario is already priced in.
• Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (2.87 TWD to 5.68 TWD) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 14.96 TWD – 40.00 TWD · fair‑value band 2.87 TWD – 5.68 TWD · the 19.10 TWD price screens above the 4.27 TWD fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Yung Zip Chemical Ind Co Ltd (4102) currently trades at 19.10 TWD, while our model-based Fair Value estimate is 4.27 TWD, implying the stock looks roughly 77.6% overvalued today. The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Yung Zip Chemical Ind Co Ltd generated revenue of 468M TWD at a net margin of -2.4%. Revenue declined 4.5% year over year. It earns a return on equity of -1.0%. Net debt stands at 57.0M TWD. Fundamentals as of Aug 13, 2026

Our scenario range runs from 2.87 TWD (bear case) to 5.68 TWD (bull case); at 19.10 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 19% below its 52-week high and 16% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at -78%, 4102 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Dividend Discount (12.97 TWD) versus Multiples (6.82 TWD). Highest evidence: Gordon GGM (70).

Key figures & financial health

Quality Score breakdown

About the company

Yung Zip Chemical Ind. Co., Ltd., together with its subsidiaries, engages in the manufacturing and trading of active pharmaceutical ingredients in Taiwan, China, Asia, the Americas, and internationally. The company offers active pharmaceutical ingredients and excipients, API intermediates, and specialty chemicals.

Full company description

Yung Zip Chemical Ind. Co., Ltd., together with its subsidiaries, engages in the manufacturing and trading of active pharmaceutical ingredients in Taiwan, China, Asia, the Americas, and internationally. The company offers active pharmaceutical ingredients and excipients, API intermediates, and specialty chemicals. It is also involved in custom research and manufacturing services; general investments; and food manufacturing. The company was founded in 1978 and is based in Taichung, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Yung Zip Chemical Ind Co Ltd reported revenue of 474M TWD in FY2025 versus 478M TWD in FY2021, a compound −0.2%/yr. Reported net income was −14.4M TWD in FY2025.

4102 screens 78% overvalued. Compare with Eli Lilly and Company →

Peer Group

Drug Manufacturers - General · 74 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.